In vivo and in vitro pharmacological characterization of SVT-40776, a novel M 3 muscarinic receptor antagonist, for the treatment of overactive bladder

British Journal of Pharmacology

Volumn 156, Issue 5, 2009, Pages 807-817

  Salcedo, C ^a   Davalillo, S ^a   Cabellos, J ^a   Lagunas, C ^a   Balsa, D ^b   Perez Del Pulgar S ^c   Ballarin M ^a   Fernandez A G ^d  

^a Research Centre   (Spain)

^b Drug Development and Clinical Research   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^d Laboratorios FERRER   (Spain)

Author keywords

Atria contractions; Carbachol; Isolated bladder tissue; Muscarinic antagonist; Overactive bladder; SVT 40776; Urinary bladder

Indexed keywords

CARBACHOL; DARIFENACIN; MUSCARINIC M3 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; SOLIFENACIN; SVT 40776; TOLTERODINE; UNCLASSIFIED DRUG; BENZHYDRYL DERIVATIVE; BENZOFURAN DERIVATIVE; CARBAMIC ACID DERIVATIVE; CRESOL; PHENYLPROPANOLAMINE; PYRROLIDINE DERIVATIVE; QUINUCLIDIN 3' YL 1 PHENYL 1,2,3,4 TETRAHYDROISOQUINOLINE 2 CARBOXYLATE MONOSUCCINATE; QUINUCLIDIN-3'-YL-1-PHENYL-1,2,3,4-TETRAHYDROISOQUINOLINE-2-CARBOXYLATE MONOSUCCINATE; QUINUCLIDINE DERIVATIVE; SVT-40776; TETRAHYDROISOQUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; BLADDER CONTRACTION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; EXPERIMENTAL GUINEA PIG; FEMALE; HEART ATRIUM CONTRACTION; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; OVERACTIVE BLADDER; PRIORITY JOURNAL; ANIMAL; BLADDER; DRUG ANTAGONISM; GUINEA PIG; HEART ATRIUM FUNCTION; HEART CONTRACTION; MUSCLE CONTRACTION; PHYSIOLOGY; SMOOTH MUSCLE;

ANIMALS; ATRIAL FUNCTION; BENZHYDRYL COMPOUNDS; BENZOFURANS; CARBAMATES; CRESOLS; GUINEA PIGS; MALE; MICE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; MYOCARDIAL CONTRACTION; PHENYLPROPANOLAMINE; PYRROLIDINES; QUINUCLIDINES; RECEPTOR, MUSCARINIC M3; TETRAHYDROISOQUINOLINES; URINARY BLADDER;

EID: 66949124700     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2008.00082.x     Document Type: Article

References (57)

1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U et al. (2003). The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the international continence society. Urology 61 : 37 49.
2. Abrams P, Andersson KE, Buccafusco JJ, Chapple C, de Groat WC, Fryer AD et al. (2006). Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 148 : 565 578.
3. Andersson KE (2002a). Overactive bladder - pharmacological aspects. Scand J Urol Nephrol Suppl 72 81.
4. Andersson KE (2002b). Potential benefits of muscarinic M3 receptor selectivity. Eur Urol Suppl 1 : 23 28.
5. Andersson KE (2004). Antimuscarinics for treatment of overactive bladder. Lancet Neurol 3 : 46 53.
6. Andersson KE, Olshansky B (2007). Treating patients with overactive blabber syndrome with antimuscarinics: heart rate considerations. BJU Int 100 : 1007 1014.
7. Andersson KE, Yoshida M (2003). Antimuscarinics and the overactive detrusor - which is the main mechanism of action? Eur Urol 43 : 1 5.
8. Balsa D, Salcedo C, Enrich A, Davalillo S, Cabellos J, Pellicer T et al. (2004). SVT-40776: a selective, competitive and reversible antagonist of the human recombinant muscarinic M3 receptor. International Continence Society 34th Annual Meeting 2004 (Abstract 260).
9. Balsa D, Salcedo C, Enrich A, Davalillo S, Cabellos J, Fernández AG (2005). Functional bladder selectivity of SVT-40776: a comparative study. 35th Annual Meeting of the International Continence Society. Montreal. P 284.
10. Barr RG, Bourbeau J, Camargo CA, Ram FS (2006). Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 61 : 854 862.
11. Brading AF (1997). A myogenic basis for the overactive bladder. Urology 50 : 57 67.
12. Caulfield MP (1993). Muscarinic receptors - characterization, coupling and function. Pharmacol Ther 58 : 319 379.
13. Chapple C, Steers W, Norton P, Millard R, Kralidis G, Glavind K et al. (2005). A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int 95 : 993 1001. (Pubitemid 40655694)
14. Chess-Williams R, Chapple CR, Yamanishi T, Yasuda K, Sellers DJ (2001). The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. J Auton Pharmacol 21 : 243 248.
15. Choppin A (2002). Muscarinic receptors in isolated urinary bladder smooth muscle from different mouse strains. Br J Pharmacol 137 : 522 528.
16. Choppin A, Eglen RM (2001). Pharmacological characterization of muscarinic receptors in mouse isolated urinary bladder smooth muscle. Br J Pharmacol 133 : 1035 1040. (Pubitemid 32762413)
17. Choppin A, Eglen RM, Hegde SS (1998). Pharmacological characterization of muscarinic receptors in rabbit isolated iris sphincter muscle and urinary bladder smooth muscle. Br J Pharmacol 124 : 883 888.
18. de Groat WC (1997). A neurologic basis for the overactive bladder. Urology 50 : 36 52.
19. Dhein S, van Koppen CJ, Brodde OE (2001). Muscarinic receptors in the mammalian heart. Pharmacol Res 44 : 161 182.
20. Eglen RM, Hegde SS, Watson N (1996). Muscarinic receptor subtypes and smooth muscle function. Pharmacol Rev 48 : 531 565.
21. Ehlert FJ, Griffin MT, Abe DM, Vo TH, Taketo MM, Manabe T et al. (2005). The M2 muscarinic receptor mediates contraction through indirect mechanisms in mouse urinary bladder. J Pharmacol Exp Ther 313 : 368 378.
22. Farrerons C, Catena J, Fernandez-Serrat A, Miquel I, Balsa D, Bonilla JI et al. (2002) Carbamates derived from arylalkylamines. PCT/ES01/00252 [WO 02/00652].
23. Fernández AG, Viayna C, Salcedo C, Davalillo S, Sanagustín J, Balsa D et al. (2005) Bladder selectivity of SVT-40776: a pharmacokinetic/pharmacodynamic (PK/PD) analysis based on preclinical and clinical studies. International Continence Society 35th Annual Meeting 2005.
24. Fetscher C, Fleichman M, Schmidt M, Krege S, Michel MC (2002). M(3) muscarinic receptors mediate contraction of human urinary bladder. Br J Pharmacol 136 : 641 643.
25. Gillberg PG, Sundquist S, Nilvebrant L (1998). Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists. Eur J Pharmacol 349 : 285 292.
26. Harriss DR, Marsh KA, Birmingham AT, Hill SJ (1995). Expression of muscarinic M3-receptors coupled to inositol phospholipid hydrolysis in human detrusor cultured smooth muscle cells. J Urol 154 : 1241 1245.
27. Hassall CJ, Stanford SC, Burnstock G, Buckley NJ (1993). Co-expression of four muscarinic receptor genes by the intrinsic neurons of the rat and guinea-pig heart. Neuroscience 56 : 1041 1048.
28. Hay-Smith J, Herbison P, Ellis G, Morris A (2005). Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 20 : CD005429.
29. Hegde SS, Eglen RM (1999). Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. Life Sci 64 : 419 428.
30. Hegde SS, Choppin A, Bonhaus D, Briaud S, Loeb M, Moy TM et al. (1997). Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br J Pharmacol 120 : 1409 1418.
31. Hellgren I, Mustafa A, Riazi M, Suliman I, Sylven C, Adem A (2000). Muscarinic M3 receptor subtype gene expression in the human heart. Cell Mol Life Sci 57 : 175 180.
32. Herbison P, Hay-Smith J, Ellis G, Moore K (2003). Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. British Medical Journal 326 : 841 844.
33. Hoover DB, Baisden RH, Xi-Moy SX (1994). Localization of muscarinic receptor MRNAs in rat heart and intrinsic cardiac ganglia by in situ hybridization. Circ Res 75 : 813 820.
34. Howell RE, Kovalsky MP (1995). Hypotensive effect of an M2-selective muscarinic antagonist in anaesthetized guinea-pigs. J Auton Pharmacol 15 : 19 26.
35. Kesten S, Jara M, Wentworth C, Lanes S (2005). Pooled clinical trial analysis of the safety of tiotropium. Chest 128 : 257S.
36. Lai FM, Cobuzzi A, Spinelli W (1998) Characterization of muscarinic receptors mediating the contraction of the urinary detrusor muscle in cynomolgus monkeys and guinea pigs. Life Sci 62 : 1179 1186.
37. Longhurst PA, Levendusky M (2000). Influence of gender and the oestrous cycle on in vitro contractile responses of the rat urinary bladder to cholinergic stimulation. Br J Pharmacol 131 : 177 184.
38. Longhurst PA, Leggett RE, Briscoe JA (1995). Characterization of the functional muscarinic receptors in the rat urinary bladder. Br J Pharmacol 116 : 2279 2285.
39. Matsui M, Motomura D, Karasawa H, Fujikawa T, Jiang J, Komiya Y et al. (2000). Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype. Proc Natl Acad Sci USA 97 : 9579 9584.
40. Matsui M, Motomura D, Fujikawa T, Jiang J, Takahashi S, Manabe T et al. (2002). Mice lacking M2 and M3 muscarinic acetylcholine receptors are devoid of cholinergic smooth muscle contractions but still viable. J Neurosci 22 : 10627 10632.
41. Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J (2006). Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 4 : CD003781.
42. Olshansky B, Foote J, Arguinzoniz M, Lheritier K, Quebe-Fehling E, Steel M (2006). The effects of darifenacin and tolterodine on Heart Rate (HR) in patients with overactive bladder. Neurourol Urodyn 25 : A124.
43. Olshansky B, Ebinger U, Egermark M, Luthra A, Rekedac A, Brum J (2008). Antimuscarinics and heart rate: results from a randomized, double-blind, placebo-controlled, 3 way crossover study in subjects over age 50. ICI 2008 July 5-8, Paris, Abst 32
44. Pontari MA, Braverman AS, Ruggieri MR Sr. (2004). The M2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction. Am J Physiol Regul Integr Comp Physiol 286 : R874 R880.
45. Romanzi LJ, Delconte A, Kralidis G (2005). Impact of darifenacin compared with tolterodine on incontinence episodes in patients with overactive bladder. Obstet Gynecol 105 : 88S.
46. Salcedo C, Balsa D, Enrich A, Davalillo S, Pellicer T, Lagunas C et al. (2003). SVT-40776, a new selective M3 muscarinic antagonist: human receptor binding profile and bladder effects in the guinea-pig. Neurourol Urodyn 22 : 382 384.
47. Schneider T, Fetscher C, Krege S, Michel MC (2004). Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther 309 : 1148 1153. (Pubitemid 38669703)
48. Shi H, Wang H, Wang Z (1999). Identification and characterization of multiple subtypes of muscarinic acetylcholine receptors and their physiological functions in canine hearts. Mol Pharmacol 55 : 497 507.
49. Stengel PW, Gomeza J, Wess J, Cohen ML (2000). M(2) and M(4) receptor knockout mice: muscarinic receptor function in cardiac and smooth muscle in vitro. J Pharmacol Exp Ther 292 : 877 885.
50. Stevens LA, Chapple CR, Chess-Williams R (2007). Human idiopathic and neurogenic overactive bladders and the role of M2 muscarinic receptors in contraction. Eur Urol 52 : 531 538.
51. Tobin G, Sjogren C (1995). In vivo and in vitro effects of muscarinic receptor antagonists on contractions and release of [3H]Acetylcholine in the rabbit urinary bladder. Eur J Pharmacol 281 : 1 8.
52. Tran JA, Matsui M, Ehlert FJ (2006). Differential coupling of muscarinic M-1, M-2, and M-3 receptors to phosphoinositide hydrolysis in urinary bladder and longitudinal muscle of the ileum of the Mouse. J Pharmacol Exp Ther 318 : 649 656.
53. Tyagi S, Tyagi P, Van le S, Yoshimura N, Chancellor MB, de Miguel F (2006). Qualitative and quantitative expression profile of muscarinic receptors in human urothelium and detrusor. J Urol 176 : 1673 1678.
54. Wang H, Han H, Zhang L, Shi H, Schram G, Nattel S et al. (2001). Expression of multiple subtypes of muscarinic receptors and cellular distribution in the human heart. Mol Pharmacol 59 : 1029 1036.
55. Wang P, Luthin GR, Ruggieri MR (1995). Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J Pharmacol Exp Ther 273 : 959 966.
56. Wein AJ, Rovner ES (2002). Definition and epidemiology of overactive bladder. Urology 60 : 7 12.
57. Yamada S, Maruyama S, Takagi Y, Uchida S, Oki T (2006). In vivo demonstration of M3 muscarinic receptor subtype selectivity of darifenacin in mice. Life Sci 80 : 127 132.